Pfizer supplies pricing data to GAO
Pfizer is turning over drug pricing data subpoenaed by the General Accounting Office, Pfizer CEO Henry McKinnell, PhD, reported Jan. 15. GAO's Jan. 3 subpoena gave the company until Jan. 14 to supply the documents (1"The Pink Sheet" Jan. 14, p. 26). "What was requested was pricing of individual products to individual customers," McKinnell said. "We were prepared to provide that information. However, we wanted to protect confidentiality. We agreed to those protections last week and the data has been provided"...
You may also be interested in...
Pfizer has until Jan. 14 to respond to the General Accounting Office's request for documents related to price reporting practices under the Medicaid drug rebate program
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.